Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2010

01-04-2010 | Short Research Report

Drug treatments in a neonatal setting: focus on the off-label use in the first month of life

Authors: Angelica Dessì, Claudia Salemi, Vassilios Fanos, Laura Cuzzolin

Published in: International Journal of Clinical Pharmacy | Issue 2/2010

Login to get access

Abstract

Objective The purpose of this work was to analyse drugs prescribed in the first month of life among a group of newborns admitted to the Neonatal Intensive Care Unit and Neonatal Pathology of Cagliari University Hospital. Method This pilot study was prospectively conducted during a 1-month period and involved all newborns admitted to our hospital that received a pharmacotherapy. After obtaining written parental consent, data collected from each newborn included date of birth, sex, gestational age and weight. Also, diagnosis and information about each drug administered during the first month of life: dose, frequency, route of administration, and indication for use was collected. Results Among the 79 newborn infants admitted to our hospital during the study period, 38 received a pharmacotherapy and were enrolled in our study. A total of 88 treatments were given: 41 (47%) followed the terms of the product license, 47 (53%) were used in an unlicensed or off-label manner. Conclusion Our results confirm this trend of drug use in the neonatological field and suggest the need to update information contained in the data sheets of medicines.
Literature
1.
go back to reference Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonat. 1999;80:F142–5.CrossRef Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonat. 1999;80:F142–5.CrossRef
3.
go back to reference Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002;25:1–5.CrossRefPubMed Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002;25:1–5.CrossRefPubMed
4.
go back to reference Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C, et al. Medicines for children licensed by the European Medicine Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol. 2006;62:947–52.CrossRefPubMed Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C, et al. Medicines for children licensed by the European Medicine Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol. 2006;62:947–52.CrossRefPubMed
5.
go back to reference Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Exp Opin Drug Saf. 2006;5:703–18.CrossRef Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Exp Opin Drug Saf. 2006;5:703–18.CrossRef
6.
go back to reference Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Weekly. 2006;136:218–22. Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Weekly. 2006;136:218–22.
7.
go back to reference Dell’Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci. 2007;29:361–7.CrossRefPubMed Dell’Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci. 2007;29:361–7.CrossRefPubMed
8.
go back to reference Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonat Med. 2005;10:115–22.CrossRef Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonat Med. 2005;10:115–22.CrossRef
9.
go back to reference Rieger-Fackeldey E, Reinhardt D, Schulze A. Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants. Pulm Pharmacol Ther. 2004;17:293–300.CrossRefPubMed Rieger-Fackeldey E, Reinhardt D, Schulze A. Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants. Pulm Pharmacol Ther. 2004;17:293–300.CrossRefPubMed
10.
go back to reference Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52:77–83.CrossRefPubMed Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52:77–83.CrossRefPubMed
Metadata
Title
Drug treatments in a neonatal setting: focus on the off-label use in the first month of life
Authors
Angelica Dessì
Claudia Salemi
Vassilios Fanos
Laura Cuzzolin
Publication date
01-04-2010
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9356-2

Other articles of this Issue 2/2010

International Journal of Clinical Pharmacy 2/2010 Go to the issue